QuantHealth has simulated more than 350 clinical trials using its AI-powered prediction engine, reporting up to 90% accuracy and significant cost and time savings for drug developers.

The company’s platform is now being deployed across 23 therapeutic areas, including oncology, immunology, cardiometabolic diseases, and gastroenterology. According to the company, the technology supports pharmaceutical teams in optimising protocol design, accelerating timelines, and prioritising assets with improved confidence.

In one example, a top-10 global pharmaceutical company used QuantHealth’s simulation platform to evaluate a Phase 2 trial for a first-in-class autoimmune therapy. The company’s engine identified a likely non-responder subgroup that could have weakened the trial outcome. This insight enabled the sponsor to refine its patient population, reduce enrollment time by 15 months, cut $31.4 million in costs, and increase the trial’s predicted probability of success by 2.8 times.

“By giving R&D teams a clearer understanding of how trials are going to perform before they begin, we’re helping them make smarter, more informed decisions,” said Orr Inbar, CEO and co-founder of QuantHealth.

“The ability to identify what works early on not only reduces the risk of failure, but also leads to major cost savings and reduced timelines. This kind of predictive insight is particularly impactful in advancing innovative assets, where every day and every dollar counts and optimizing outcomes is critical to success.”

The platform has been applied in 110 simulations for first-in-class (FIC) therapies and 168 Phase 2 trials, which typically present high failure rates. According to QuantHealth, FIC programmes are among the most challenging in drug development, with just 8% of 2023–2024 submissions reaching regulatory approval. Industry-wide, Phase 2 success rates typically fall below 30%.

QuantHealth’s technology is undergoing third-party validation through pharmaceutical partnerships and external peer review.

“First-in-class assets are where the uncertainty is highest, and the stakes are greatest,” said Brigham Hyde, CEO and co-founder of Atropos Health. “Through our Evidence Network, QuantHealth is able to leverage high-quality real-world data in a way that supports rigorous simulation where better predictions can help teams confidently advance transformative therapies and bring hope to patients in the most underserved disease areas.”

The announcement follows the launch of QuantHealth’s Large Real-World Drug Model (LRDM v1.0), described by the company as a clinical trial foundation model that can predict drug effectiveness and patient outcomes. The company says it plans to release version 1.1 later this year, with new capabilities and a broader scope.

QuantHealth continues to grow its industry partnerships and expand the number of simulations on its platform, aiming to support pharmaceutical companies in bringing new therapies to market more efficiently.